CHINOOK THERAPEUTICS
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.
CHINOOK THERAPEUTICS
Industry:
Biotechnology
Founded:
2019-01-01
Address:
Vancouver, Alberta, Canada
Country:
Canada
Website Url:
http://www.chinooktx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
171 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Apache Microsoft Exchange Online Office 365 Mail
Similar Organizations
Asher Bio
Asher Bio is a biotechnology company that specializes in the fields of therapeutics builds better immunotherapy for cancer.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Columbia Pulp
Columbia Pulp is an agriculture Company turning waste straw into pulp for papermaking and lignin for petrochemical replacements.
Invaio Sciences
Invaio Sciences is a technology company that is dedicated to solving pressing agriculture, nutrition, and environmental challenges.
Mnemo Therapeutics
Mnemo Therapeutics specializes in biotechnology and life science.
Sigilon Therapeutics
Sigilon is a biotech company which specializes in creating immune privileged products for unmet clinical needs.
Vera Therapeutics
Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-06-02 | Aduro BioTech | Aduro BioTech acquired by Chinook Therapeutics | N/A |
Investors List
OrbiMed
OrbiMed investment in Post-IPO Equity - Chinook Therapeutics
Avidity Partners
Avidity Partners investment in Post-IPO Equity - Chinook Therapeutics
Versant Ventures
Versant Ventures investment in Post-IPO Equity - Chinook Therapeutics
Apple Tree Partners
Apple Tree Partners investment in Post-IPO Equity - Chinook Therapeutics
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - Chinook Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Post-IPO Equity - Chinook Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Post-IPO Equity - Chinook Therapeutics
Northleaf Capital Partners
Northleaf Capital Partners investment in Post-IPO Equity - Chinook Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - Chinook Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Chinook Therapeutics
Official Site Inspections
http://www.chinooktx.com Semrush global rank: 3.33 M Semrush visits lastest month: 4.8 K
- Host name: ec2-54-176-110-96.us-west-1.compute.amazonaws.com
- IP address: 54.176.110.96
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95141
More informations about "Chinook Therapeutics"
Chinook Therapeutics - Crunchbase Company Profile
Www.chinooktx.com ; 16,106; Highlights. Acquisitions 1. obfuscated. Total Funding Amount . Unlock for free . Contacts 119. Employee Profiles 7. ...See details»
Novartis
Apr 29, 2025 Patient organization funding Payments to healthcare professionals Public policy A living wage A safe workplace Animal research Environmental, social and governance. Learn …See details»
Chinook Therapeutics - LinkedIn
Chinook Therapeutics is now a Novartis Company! On August 11, 2023, Novartis completed its acquisition of Chinook. Follow Novartis to stay updated on atrasentan, zigakibart (BION-1301) …See details»
Chinook Therapeutics - Craft
Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. It offers atrasentan, a potent and selective endothelin A (ETA) receptor antagonist; …See details»
Chinook Therapeutics Enters into Agreement to be Acquired by …
Jun 12, 2023 Chinook Therapeutics, Inc. Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value …See details»
Chinook Therapeutics (KDNY) | Portfolio | Versant Ventures
Chinook is developing precision medicines for kidney diseases. The company is applying its proprietary discovery platform, which leverages single cell RNA sequencing, human-derived …See details»
Chinook Therapeutics, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Chinook Therapeutics, Inc. of East Hanover, NJ. Get the latest business insights from Dun & Bradstreet.See details»
Chinook Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Www.chinooktx.com. Public Company | Subsidiary Company | 2019 | Canada | 100-250 | NASDAQ: KDNY | www.chinooktx.com. Last update 09 Apr 2025. Overview. Pipeline. Deal. ...See details»
8-K - SEC.gov
These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov, the Novartis website at https://www.novartis.com and Chinook’s website at …See details»
CHINOOK THERAPEUTICS CLOSES MERGER WITH ADURO …
Combined CompanyWillHave Over $275 Million in Operating Capital andTrade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 …See details»
Aduro Biotech and Chinook Therapeutics Announce Definitive
Jun 2, 2020 Management and Organization ... For more information visit www.chinooktx.com. Non-Solicitation This communication is for informational purposes only and does not constitute …See details»
Novartis completes acquisition of Chinook Therapeutics
Aug 11, 2023 Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront; Deal brings two phase 3 assets in development for IgAN; …See details»
Chinook Therapeutics Announces the Appointment of Robert W
SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc., (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization …See details»
Chinook Therapeutics Enters Into Agreement to be Acquired by …
Jun 12, 2023 Corporate Office. 623 Fifth Avenue 14th Floor New York, NY 10022. P: (212) 887-2100 E: [email protected]See details»
Chinook Therapeutics Enters into Agreement to be Acquired
Jun 12, 2023 Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of …See details»
Chinook Therapeutics to Present at SVB Securities Global …
SEATTLE, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of …See details»
Chinook Therapeutics Announces the Appointment of Andrew …
Feb 15, 2023 Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced the appointment of Andrew Oxtoby as chief commercial officer (CCO).See details»
Chinook Therapeutics Announces the Appointment of Robert W.
SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of …See details»
Chinook Therapeutics Announces New Employment Inducement …
VANCOUVER, British Columbia and SEATTLE, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on …See details»
Chinook Therapeutics to Present at the 10th Annual SVB Leerink …
VANCOUVER, British Columbia and SEATTLE, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the …See details»